Phase 1 Ovarian Cancer Trial, Recruiting NCT05410717 Sponsor: Second Affiliated Hospital of Guangzhou Medical University Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 1 Ovarian Cancer Trial, Recruiting

NCT05410717
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with advanced ovarian cancer, or another type of cancer that has a specific protein called "claudin6" present on the cancer cells
  • You are expected to live for more than 12 weeks
  • Your heart, lungs, liver, and kidneys are working well enough as shown by medical tests
  • A sample of your own natural killer (NK) immune cells can be collected and successfully modified in the lab to meet certain activity levels against cancer cells (the trial team will assess this)
  • You are willing and able to read, understand, and sign a consent form agreeing to take part

Who may not be able to join:

  • You have previously received any form of gene therapy
  • Your tumor is larger than 25 cm in size
  • You have a serious viral infection such as hepatitis B, hepatitis C, or HIV
  • You have tested positive for HIV
  • You have previously had a liver or kidney transplant
  • You currently have an active infection caused by bacteria, a virus, fungi, or similar
  • You are pregnant or currently breastfeeding
  • You are taking regular steroid medication at a certain daily dose or higher (confirm with trial site for exact details)
  • You have another serious health condition that the trial doctors feel makes participation unsuitable
  • There are any other reasons the trial doctors feel make participation unsuitable (confirm with trial site)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Zhenfeng Zhang, MD, PHD, Second Affiliated Hospital of Guangzhou Medical University

Phone: +862039195966

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Registry
ClinicalTrials.gov
Start date
1 June 2022
Est. completion
1 June 2030

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Safety by Common Terminology Criteria for Adverse Events (CTCAE) V5.0

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov